Clinical usefulness of FDG–PET/CT for the evaluation of various types of adult T-cell leukemia

Sawako Nakachi, Masahiro Okada, Satoko Morishima, Yurika Agarie, Sakiko Kitamura, Sachie Uchibori, Shouhei Tomori, Taeko Hanashiro, Natsuki Shimabukuro, Keita Tamaki, Iori Tedokona, Kazuho Morichika, Yukiko Nishi, Takeaki Tomoyose, Kennosuke Karube, Takuya Fukushima, Sadayuki Murayama and Hiroaki Masuzaki

Division of Endocrinology, Diabetes and Metabolism, Hematology and Rheumatology (Second Department of Internal Medicine), Graduate School of Medicine, University of the Ryukyus, Nishihara, Japan; Department of Radiology, Graduate School of Medical Science, University of the Ryukyus, Nishihara, Japan; Internal Medicine, Heart-Life Hospital, Nakagusuku, Japan; Department of Pathology and Cell Biology, Graduate School of Medicine, University of the Ryukyus, Nishihara, Japan; Laboratory of Immunohematology, School of Health Sciences, Faculty of Medicine, University of the Ryukyus, Nishihara, Japan

ABSTRACT

Purpose: The aim was to explore undefined useful indices for clinically grading adult T-cell leukemia (ATL) using [18F] 2-fluoro-2-deoxyglucose (FDG) – positron emission tomography/computed tomography (PET/CT).

Methods: A total of 28 patients with ATL (indolent, 9; aggressive, 19) were enrolled; all patients with aggressive ATL underwent FDG–PET/CT before chemotherapy. Patients with indolent ATL underwent FDG–PET/CT at the time of suspected disease progression and/or transformation; some received lymph node biopsy. The quantitative parameters maximum standardized uptake values (SUVmax), and mean and peak SUV, metabolic tumor volume (MTV), and volume-based total lesion glycolysis were calculated with the margin threshold as 25%, and 50% of the SUVmax for all lesions.

Results: All parameters except for MTV-25% showed significant differences (P ≤ 0.05) in differentiating the aggressive type from the indolent type of ATL. Areas under the curve for receiver-operating characteristic (ROC) analysis regarding the series of parameters investigated ranged from 0.75 to 0.92; this indicated relatively high accuracy in distinguishing the aggressive type from the indolent type. No malignant findings were detected in lymph node biopsies in indolent ATL patients with lymphadenopathy.

Discussion: We performed evaluation of a line of parameters of FDG–PET, thereby demonstrating their significantly high accuracy for grading malignancy in ATL patients. In particular, low accumulation of FDG in indolent ATL patients with lymphadenopathy might predict that it is not a sign of disease transformation, but rather a reactive manifestation.

Conclusion: FDG–PET/CT findings could be useful for clinically grading ATL.

KEYWORDS

Adult T-cell leukemia; indolent type; aggressive type; positron emission tomography; standardized uptake value; metabolic tumor volume; total lesion glycolysis; volume-based parameter

© 2017 Informa UK Limited, trading as Taylor & Francis Group

CONTACT
Hiroaki Masuzaki hiroaki@med.u-ryukyu.ac.jp Division of Endocrinology, Diabetes and Metabolism, Hematology, Rheumatology (Second Department of Internal Medicine), Graduate School of Medicine, University of the Ryukyus, 207 Uehara, Nishihara, Okinawa 903-0215, Japan; Masahiro Okada okada777@med.u-ryukyu.ac.jp Department of Radiology, Graduate School of Medical Science, University of the Ryukyus, 207 Uehara, Nishihara, Okinawa 903-0215, Japan

© 2017 Informa UK Limited, trading as Taylor & Francis Group
**Introduction**

Patients with aggressive adult T-cell leukemia (ATL) (i.e., acute, lymphoma and unfavorable chronic types) require intensive treatment, whereas those with indolent ATL (i.e., favorable chronic and smoldering) need mild management as a subtype of chronic lymphoid leukemia [1,2]. Patients with indolent-type ATL usually exhibit skin lesions and/or leukocytosis with increased levels of abnormal lymphocytes, but show no lymphadenopathy or involvement of organs other than skin or lung. Most patients with indolent ATL are treated with watchful waiting until disease progression to acute crisis. We sometimes find patients with indolent ATL with lymphadenopathy, which represents suspected signs of disease progression and/or transformation; lymph node biopsy is usually performed for accurate diagnosis. In these patients, histologically proven ATL-involved lymphadenopathy or other ATL lesions (pleural effusion, ascites or involvement of CNS, bone, gastrointestinal tract, liver or spleen) are required for diagnosis of acute-type ATL.

Diagnostic imaging plays a critical role in clinical staging and evaluation of efficacy in patients with malignant lymphoma [3,4]. In particular, [18F] 2-fluoro-2-deoxyglucose (FDG)-positron emission tomography (PET) provides considerable information relative to other imaging modalities such as CT and 67Ga scintigraphy. FDG–PET is widely used to predict prognosis in solid malignancies including lung, and head and neck carcinomas [5]. FDG uptake in aggressive non-Hodgkin’s lymphoma (NHL) is significantly higher than in indolent lymphoma, and standardized uptake values (SUV) are helpful in distinguishing between indolent and aggressive NHL [6]. Furthermore, recent improvements in FDG–PET/CT software allow measurement of disease burden indicators, such as metabolic tumor volume (MTV) and total lesion glycolysis (TLG) [5,7]. MTV is measured by a semiautomatic software with an automatic iso-contour threshold algorithm. TLG is also a volume-based parameter, shown to be a promising prognostic index in various malignancies including malignant lymphoma [8,9]. However, intensive analyses of FDG–PET in ATL patients have not been fully reported.

The purpose of the present study was to explore the potential relationship between malignant grade and analytical values as assessed using PET/CT volumetric techniques including SUV, MTV and TLG.

**Materials and methods**

**Patients**

Twenty-eight patients diagnosed with ATL (nine with smoldering or chronic, and 19 with lymphoma or acute types) were enrolled. All patients underwent skin (n = 14) or lymph node (n = 6) biopsies or hematological diagnosis from peripheral blood (n = 13). Patients received [18F-FDG] PET/CT between July 2013 and November 2015. Evaluation of clinical stage included complete blood count, biochemistry, chest X-ray, CT scans of the neck, chest and abdomen, FDG–PET/CT, and bone marrow examination. The present study was approved by the institutional review board at our university hospital (approval number 800), and all participants gave written informed consent.

**FDG–PET and image analysis**

A PET/CT scanner (Biograph mCT, Siemens Healthcare, Erlangen, Germany) with time-of-flight (TOF) was used in the present study. The image analysis was performed using a workstation with syngo-via software (Siemens Healthcare, Erlangen, Germany). CT scanning parameters were as follows: peak X-ray tube voltage, 120 kVp; tube current, automatic exposure control (care dose 4D), 90 mA; field of view, 50 × 50 cm; and beam width, 1.2 mm × 32. Whole-body PET/CT images were acquired at 1 hour after intravenous injection of 3.7 MBq of FDG per 1 kg body weight (upper limit, 340 MBq); an emission scan was obtained from the top of the skull to the upper thigh or soles of the feet, for 120 s/bed per field of view each covering 92.88 mm, at an axial sampling thickness of 2 mm/ slice (1 bed position 216 mm; each covering). Peak SUV (SUVpeak) [10] was defined as the average SUV within a small, fixed-size region of interest (ROIpeak) centered on a high-uptake region of the tumor. Values of maximum SUV (SUVmax) and TLG with two variable margin thresholds were also acquired for analysis. TLG of a target lesion was calculated as the mean SUV (SUVmean) × MTV, which considers both the metabolic activity and tumor burden. SUVmean was measured by setting margin thresholds of 25%, and 50% of SUVmax for each lesion, resulting in SUVmean-25%, and SUVmean-50%, respectively. MTV was also measured by setting the margin thresholds as 25%, and 50% of SUVmax, as proposed by Ceriani et al. [11] and by Boellard et al. [12] for evaluation of tumoral lesions. On a patient basis, SUVmax was defined as the highest SUVmax among those for all lesions, and TLG for a patient was defined as the sum of all those lesions.

**Statistical analysis**

Between-group differences in PET parameters were evaluated using Fisher’s exact test and Student’s t-test as appropriate. Two sided P values <0.05 were
Results

Characteristics of patients studied

The clinical and pathologic characteristics of the 28 patients with ATL are shown in Table 1. Each patient's ATL subtype was determined according to Shimoyama criteria [1], which are internationally accepted for classification of ATL subtype. All patients with aggressive ATL (lymphoma, acute) underwent FDG-PET/CT scans prior to chemotherapy. Patients with indolent ATL (smoldering, chronic) underwent at the time of suspected disease progression and/or transformation. Among them, two patients underwent FDG-PET/CT scans when they relapsed. One patient with the chronic type received chemotherapy at 4 months before PET/CT, and another patient with the acute type received umbilical-cord blood transplantation at 6 months before PET/CT. The median age was 63.5 (range, 37–81) years with a male:female ratio of 1:1. Nineteen of the 28 patients had aggressive ATL (lymphoma, acute). Twenty of the 28 patients had a low performance status score (0–1). Twenty-six patients were categorized as being at an advanced clinical stage (III–IV). In 12 patients, FDG–PET/CT was performed from the top of the skull to the upper thigh. In the other patients, FDG–PET/CT was performed from the top of the skull to the sole of the feet.

All the nine patients with indolent ATL underwent FDG–PET/CT at a time when they showed lymphadenopathy; this is a suspected sign of disease progression and/or transformation. Lymph node biopsy was performed in six of these patients; however, pathological findings were HTLV-I associated lymphadenitis or dermatopathic lymphadenitis, which were reactive disorders [15,16].

Parameters for glucose metabolism in all lesions

A representative patient with indolent ATL exhibited low accumulation of FDG (Figure 1), whereas a representative patient with aggressive ATL showed apparently higher accumulation of FDG (Figure 2). The median PET/CT parameters of all target lesions before treatment or at the time of suspected disease progression are listed in Table 2. FDG-avid lesions and parameters in each patient are detailed in Table 3. All patients except one showed FDG uptake in lymph nodes, and some had FDG-avid extra-nodal lesions such as in the spleen, skin, bone and liver. Patient 22 had chronic-type ATL, with higher SUV_{max} and 50% TLG than the rest of the indolent group, and showed systemic lymphadenopathy, splenomegaly, fever and liver dysfunction. A lymph node biopsy showed reactive lymphadenitis. As this patient was suspected of having chronic active Epstein-Barr virus infection (CAEBV) because of high peripheral levels of anti-EBV VCA-IgG, EBV-EA IgG, and EBV-DNA in peripheral blood, we considered that high FDG accumulation in this patient might reflect CAEBV activity [17].

All of the pertinent parameter values for aggressive ATL were significantly higher than those for indolent ATL (Table 4). In patients with indolent ATL, FDG accumulation of the chronic type was higher than that of the smoldering type, albeit that there was no statistical difference (Table 2). ROC analyses were performed to evaluate the usefulness of each PET/CT parameter in discriminating malignant grade. The AUC in ROC analysis of SUV, MTV and TLG ranged from 0.75 to 0.9, indicating high accuracy (Table 5).
Inter-observer agreement

The two nuclear medicine radiologists’ inter-observer agreement for presence or absence of lesions shown by FDG–PET/CT is detailed in Table 6. The $\kappa$ value for all nodal regions was 0.97, indicating good inter-observer agreement ($\kappa > 0.4$). Their $\kappa$ values for individual nodal regions were also satisfactory.

Discussion

The present study demonstrated that the PET/CT parameters (SUV, MTV and TLG) investigated were useful predictors of grade of malignant tumor in ATL patients. We analyzed the clinical utility of PET/CT parameters in distinguishing indolent ATL from aggressive ATL. A series of PET/CT parameter values (SUVmax, SUVpeak, SUVmean-25%, SUVmean-50%, MTV-25%, MTV-50%, TLG-25% and TLG-50%) for aggressive ATL were significantly higher than those for indolent ATL. It was also demonstrated that the AUC for these PET/CT parameters ranged from 0.75 to 0.92, indicating high accuracy in distinguishing indolent ATL from aggressive ATL. These results demonstrate that a series of PET/CT parameters other than SUVmax are also clinically-useful parameters comparable to SUVmax in evaluating the malignancy grade of ATL. Our results also clearly demonstrated that overall inter-observer agreement between FDG-PET/CT findings was excellent.

In FDG-PET/CT, FDG uptake and subsequent hypermetabolism of glucose is a reliable surrogate marker of aggressive biology in solid tumors and lymphomas [4,18]. SUV has been used as a quantitative parameter for glucose metabolism, and SUVmax for a tumor lesion has been widely used as a survival predictor or in the grading of several solid tumors and some lymphomas [5,8,9]. However, it should be noted that SUVmax reflects the metabolic activities of the most aggressive cells, which does not necessarily align with the prognostic index. In some malignancies, TLG has recently been suggested as being a better metabolic parameter than SUVmax in FDG-PET/CT because TLG reflects the metabolic tumor burden [7]. Among a variety of malignant lymphomas, Hodgkin lymphoma and diffuse large B-cell lymphoma show a high level of FDG uptake, indicating representative ‘FDG-avid lymphomas’ [3]. In contrast, other studies have demonstrated lower rates of PET detection for cutaneous T-cell lymphoma and extra-nodal marginal zone lymphoma [19]. However, there have been very few reports concerning FDG-PET studies on ATL [20–25].

ATL is notably characterized by multiple tumor lesions, which indicate a large tumor burden leading to multiple-organ failure [1]. We therefore...
hypothesized that TLG could help evaluate tumor burden and extent in ATL patients. The present study suggests that TLG, which reflects total metabolic tumor volume, also reflects aggressiveness and SUVmax in ATL (Table 5). MTV and TLG are immediately measured after ROI placement on the lesion by PET software, and facilitate measurement of lesion volume. As expected, our data demonstrates that both the intensity of FDG uptake and metabolic volume were significantly lower in the indolent type relative to the aggressive type (Table 4), even though all the patients with the indolent type underwent FDG-PET/CT at the time when we suspected disease progression and/or transformation in these patients. We could not compare advantages of TLG with other FDG–PET parameters in the current study due to the

Table 2. PET/CT parameters according to ATL type.

| Parameter | Indolent | | | Aggressive | | |
|-----------|---------|-------|--------|-----------|-------|
|           | Median  | (range) | Median  | (range) | Median  | (range) |
| SUVmax    | 4.6 (1.9–7.6) | 6.6 (3.1–14.6) | 17.0 (6.0–27.9) | 14.1 (6.6–41.6) |
| SUVpeak   | 3.1 (1.9–5.36) | 5.1 (2.6–13.3) | 10.9 (3.3–23.0) | 11.1 (3.9–31.4) |
| SUVmean25%| 2.0 (0.97–3.4) | 3.5 (1.4–6.4) | 6.7 (2.4–12.9) | 6.9 (2.8–21.7) |
| SUVmean50%| 3.0 (1.3–5.2) | 4.6 (2.3–11.7) | 11.9 (4.0–17.6) | 10.1 (4.5–28.9) |
| MTV25%    | 70.4 (10.3–470.6) | 174.4 (34.1–123.2) | 325.0 (18.7–740.8) | 383.6 (78.1–1772) |
| MTV50%    | 11.6 (4.9–91.2) | 48.3 (28–52) | 82.8 (2.62–151.1) | 97.8 (28–397.1) |
| TLG25%    | 130.2 (8.0–483.2) | 319.5 (103.5–749.2) | 982.4 (72.3–2776.5) | 1565 (193–4606.8) |
| TLG50%    | 34.1 (5.7–129.4) | 89.2 (83–397.7) | 208 (16.7–1325.3) | 607 (90–2776.3) |

Abbreviations: SUV: standardized uptake value; MTV: metabolic tumor volume; TLG: total lesion glycolysis.

Figure 2. 2-Fluoro-2-deoxyglucose (FDG)-positron emission tomography/computed tomography (FDG-PET/CT) imaging of a 56-year-old male with representative acute-type aggressive adult T-cell leukemia (ATL). (A) FDG-PET maximum intensity projection (MIP) whole-body image. Images show subcutaneous regions of hands (black arrows) and soles of the feet (empty arrows). (B) Cervical region (red arrow-heads) of integrated PET–CT, axial view. (C) Hepatic and splenic regions of integrated PET–CT, axial view. (D) Inguinal region (red arrow-heads) of integrated PET–CT, axial view. (A) A typical aggressive case was selected. This case shows several lymphadenopathy, hepatomegaly, splenomegaly, and skin lesions. MIP of FDG-PET shows multiple lesions (neck, axilla, mediastinum, para-aorta, ili, inguinal lymph node regions, liver, spleen and subcutaneous regions of the hand and planta) as high accumulations of FDG (A). The cervical plane depicts high accumulations of FDG in bilateral submandibular (SUVmax, 10.16) and deep internal jugular (SUVmax, 8.56) lymphadenopathies (B), liver (SUVmax, 7.92) and spleen (SUVmax, 8.55) (C), bilateral inguinal (SUVmax, 6.51) and palmar subcutaneous regions (SUVmax, 6.51) (D).
relatively few subjects. Further studies with larger cohorts are required, both to verify our findings, and to elucidate the usefulness of TLG in predicting prognosis and aggressive transformation in patients with ATL.

We also used PET–CT to optimize selection of biopsy sites in patients with suspected disease transformation, by targeting lymph nodes with the highest SUVmax values. It should be noted that there was concordance between low FDG/PET parameter values and no malignant pathological findings from lymph node biopsy. These findings suggest that low positive FDG/PET parameters in indolent ATL patients with lymphadenopathy might predict that it is not a sign of disease transformation from indolent type to aggressive type, but rather a reactive manifestation.

In the present study, we endeavored to optimize the margin threshold for both MTV and TLG measurements. It is widely accepted that the optimal margin threshold has not been established [11,12]. Therefore, we assessed two margin thresholds, 25 and 50%. There was no difference in margin thresholds between 25 and 50% except for the MTV-25% (Tables 4 and 5). In calculating MTV, a high threshold

### Table 3. The profile of FDG-avid lesions and parameters in each patient.

| Age  | Gender | Type       | Stage | Lesion of FDG uptake                     | SUVmax | 50% TLG |
|------|--------|------------|-------|-----------------------------------------|--------|---------|
| 1    | 70     | M          | Acute | L/N, mediastinal tumor                   | 15.68  | 749.1   |
| 2    | 60     | F          | Acute | L/N, lung, spleen                        | 6.56   | 164.8   |
| 3    | 52     | F          | Acute | L/N, spleen, liver                       | 13.69  | 181.9   |
| 4    | 69     | F          | Acute | L/N, liver, skin, stomach orbital tumor, muscle | 32.45  | 1094.1  |
| 5    | 64     | F          | Acute | lung, intestine                          | 14.61  | 2778.3  |
| 6    | 37     | M          | Acute | L/N, spleen, bone                        | 39.84  | 447.6   |
| 7    | 67     | F          | Acute | L/N, spleen, liver                       | 11.29  | 90.0    |
| 8    | 63     | M          | Acute | L/N, skin                                | 23.41  | 801.6   |
| 9    | 69     | F          | Acute | L/N, lung, bone                          | 9.03   | 464.7   |
| 10   | 56     | M          | Acute | L/N, spleen                              | 6.73   | 802.0   |
| 11   | 72     | F          | Acute | L/N, spleen                              | 41.6   | 227.4   |
| 12   | 56     | M          | Acute | L/N, skin, spleen                        | 12.99  | 1656.6  |
| 13   | 76     | F          | Acute | L/N, skin, spleen                        | 27.89  | 1138.2  |
| 14   | 63     | M          | Lymphoma | L/N, spleen, CNS                     | 23.79  | 1214.1  |
| 15   | 66     | M          | Lymphoma | L/N                                  | 5.99   | 43.5    |
| 16   | 73     | F          | Lymphoma | L/N                                   | 16.99  | 208.0   |
| 17   | 78     | M          | Lymphoma | L/N, skin                             | 11.8   | 27.1    |
| 18   | 69     | F          | Lymphoma | L/N                                  | 10.4   | 16.7    |
| 19   | 47     | M          | Chronic | L/N                                  | 3.06   | 83.0    |
| 20   | 55     | M          | Chronic | L/N, spleen                           | 6.61   | 39.2    |
| 21   | 61     | F          | Chronic | L/N, spleen                           | 14.55  | 307.7   |
| 22   | 59     | F          | Smoldering | L/N                               | 7.56   | 59.5    |
| 23   | 59     | F          | Smoldering | L/N                               | 1.86   | 5.67    |
| 24   | 43     | M          | Smoldering | L/N                                  | 4.89   | 12.6    |
| 25   | 81     | F          | Smoldering | L/N                                  | 2.41   | 129.4   |
| 26   | 64     | M          | Smoldering | L/N                                  | 4.73   | 18.9    |
| 27   | 76     | M          | Smoldering | L/N                                  | 4.46   | 49.2    |
| 28   | 64     | M          | Smoldering | L/N                                  | 4.73   | 18.9    |

Abbreviations: SUV: standardized uptake value; TLG: total lesion glycolysis; L/N: lymph node; CNS: central nervous system.

### Table 4. Comparisons of PET parameters according to malignant grade.

| Parameter                  | Indolent (n = 10) | Aggressive (n = 18) | P value |
|----------------------------|------------------|---------------------|---------|
| SUVmax average (SD)        | 5.6 (±3.8)       | 17.8 (±11.0)        | 0.003   |
| SUVpeak average (SD)       | 4.4 (±6.6)       | 13.0 (±8.2)         | 0.006   |
| SUVmean25% average (SD)    | 2.6 (±1.7)       | 8.1 (±5.1)          | 0.004   |
| SUVmean50% average (SD)    | 3.8 (±2.6)       | 12.4 (±7.3)         | 0.002   |
| MTV25% average (SD)        | 168.8 (±174.8)   | 490.9 (±398.9)      | 0.07    |
| MTV50% average (SD)        | -                |                     |         |
| TLG25% average (SD)        | 84.0 (±93.1)     | 706.8 (±711.9)      | 0.02    |
| TLG50% average (SD)        |                 |                     |         |

Abbreviations: SUV: standardized uptake value; MTV: metabolic tumor volume; TLG: total lesion glycolysis; SD: standard deviation.

### Table 5. Area under the curve obtained using receiver-operating characteristic curve analysis.

| Parameter | AUC  | 95% CI | P value |
|-----------|------|--------|---------|
| SUVmax    | 0.91 | 0.79–1.00 | –       |
| SUVmean25%| 0.90 | 0.78–0.99 | 0.53    |
| SUVmean50%| 0.92 | 0.81–0.99 | 0.69    |
| SUVpeak   | 0.89 | 0.76–1.00 | 0.41    |
| MTV25%    | 0.75 | 0.55–0.94 | 0.12    |
| MTV50%    | 0.81 | 0.65–0.97 | 0.25    |
| TLG25%    | 0.83 | 0.69–0.99 | 0.27    |
| TLG50%    | 0.85 | 0.71–1.0  | 0.35    |

Abbreviations: SUV: standardized uptake value; MTV: metabolic tumor volume; TLG: total lesion glycolysis; AUC: area under the curve; CI: confidential interval.

Note: The AUC of the SUVmax was compared for each parameter.

### Table 6. Inter-observer agreement for qualitative analysis of lesions shown by FDG–PET/CT.

| Parameter | k    |
|-----------|------|
| All nodal regions | 0.97 |
| Nodal regions |   |
| Cervical | 0.906 |
| Supraclavicular | 0.976 |
| Mediastinal | 0.965 |
| Abdominal | 0.941 |
| Pelvic | 0.953 |
| Spleen | 1.000 |

Abbreviations: SUV: standardized uptake value; MTV: metabolic tumor volume; TLG: total lesion glycolysis; SD: standard deviation.
tends to underestimate tumor burden, and a low threshold tends to overestimate tumor burden.

The present study had some limitations. First, analytical methods may fail to detect malignancy-associated FDG accumulation in skin lesions, peripheral blood and intestine lesions, partly because physiological or pathophysiological accumulation independent of malignancies may interfere; in addition, very small lesions may be below the limits of spatial resolution. Even though skin invasion by ATL was proven by biopsy, FDG uptake would not be detected in some cases. In the present study, 14 of 28 patients had skin lesions. Although their PET images were negative, skin lesions were proven by biopsy in 7 of 14 patients with skin lesions. It is therefore possible that a false-negative would be attributed to the flatness of the lesions as well as to earlier disease stage. Second, the number of ATL patients in this study was not large. We therefore could not ascertain optimal cut-off values for PET/CT parameters to differentiate between aggressive and indolent ATL types. Further studies with larger study cohorts are needed to verify and enlarge on our findings, particularly the relationship between FDG–PET/CT parameters and prognosis among aggressive ATLs.

Third, although patients in whom ATL was suspected to have transformed from indolent to aggressive type underwent FDG–PET/CT, their uptake was low, which suggests that FDG uptake in indolent types may be reactive.

Fourth, due to the small number of patients, FDG PET/CT parameters overlapped at the lower end of the aggressive group and the upper end of the indolent group.

In summary, the present study showed some PET–CT parameters – SUV, MTV, and TLG – were accurate indicators of malignancy grade in patients with ATL; and that related FDG–PET parameters can potentially indicate need and optimal biopsy site for patients in whom ATL progression or transformation is suspected.

**Acknowledgments**

We are grateful to T. Miyagi, A. Yamanoha, K. Kirimata and M. Ohama at Heart-Life Hospital for their invaluable help. We also thank Y. Murayama, M. Shimoji, Y. Kishimoto, I. Asato, M. Hirata and C. Noguchi for their assistance.

**Disclosure statement**

The authors declare that they have no conflict of interest.

**Funding**

This work was supported by the Project for Formation of Life Science Network (pharmaceutical field) and the Promotion Project of Medical Clustering of Okinawa Prefecture, and a grant from the Okinawa Prefecture for Promotion of Advanced Medicine.

**Notes on contributors**

*Sawako Nakachi*, MD, PhD, is an assistant professor of hematology in the Division of Endocrinology, Diabetes and Metabolism, Hematology and Rheumatology at the Graduate School of Medicine, University of the Ryukyus.

*Masahiro Okada*, MD, PhD, is a senior lecturer of nuclear medicine in the Department of Radiology, Graduate School of Medical Science, University of the Ryukyus.

*Satoko Morishima*, MD, PhD, is an associate professor of hematology in the Division of Endocrinology, Diabetes and Metabolism, Hematology and Rheumatology at Graduate School of Medicine, University of the Ryukyus.

*Yurika Agarie*, MD, is a clinical fellow of nuclear medicine in the Department of Radiology, Graduate School of Medical Science, University of the Ryukyus.

*Sakiko Kitamura*, MD, is a clinical fellow of hematology in the Division of Endocrinology, Diabetes and Metabolism, Hematology and Rheumatology at the Graduate School of Medicine, University of the Ryukyus.

*Sachie Uchibori*, MD, is a clinical fellow of hematology in the Division of Endocrinology, Diabetes and Metabolism, Hematology and Rheumatology at the Graduate School of Medicine, University of the Ryukyus.

*Shouhei Tomori*, MD, is a clinical fellow of hematology in the Division of Endocrinology, Diabetes and Metabolism, Hematology and Rheumatology at the Graduate School of Medicine, University of the Ryukyus.

*Taeko Hanashiro*, MD, is a clinical fellow of hematology in the Division of Endocrinology, Diabetes and Metabolism, Hematology and Rheumatology at the Graduate School of Medicine, University of the Ryukyus.

*Natsuki Shimabukuro*, MD, is a clinical fellow of hematology in the Division of Endocrinology, Diabetes and Metabolism, Hematology and Rheumatology at the Graduate School of Medicine, University of the Ryukyus.

*Keita Tamaki*, MD, is a clinical fellow of hematology in the Division of Endocrinology, Diabetes and Metabolism, Hematology and Rheumatology at the Graduate School of Medicine, University of the Ryukyus.

*Iori Tedokon*, MD, is a clinical fellow of hematology in the Division of Endocrinology, Diabetes and Metabolism, Hematology and Rheumatology at the Graduate School of Medicine, University of the Ryukyus.

*Kazuho Morichika*, MD, is a Graduate School student of hematology in the Division of Endocrinology, Diabetes and Metabolism, Hematology and Rheumatology at the Graduate School of Medicine, University of the Ryukyus.

*Yukiko Nishi*, MD, is a Graduate School student of hematology in the Division of Endocrinology, Diabetes and Metabolism, Hematology and Rheumatology at the Graduate School of Medicine, University of the Ryukyus.

*Kazuo Morishita*, MD, is a professor in the Laboratory of Immunohematology, School of Health Sciences, Faculty of Medicine, University of the Ryukyus.

*Kennosuke Karube*, MD, PhD, is a professor of pathology in the Department of Pathology and Cell Biology, Graduate School of Medicine, University of the Ryukyus.

*Takeaki Tomoyose*, MD, PhD, is a chief of hematologist at the Heart-life Hospital.
Sadayuki Murayama, MD, PhD, is a professor in the Department of Radiology, Graduate School of Medical Science, University of the Ryukyus.

Hiroaki Masuzaki, MD, PhD, is a professor of endocrinology, diabetes and metabolism in the Division of Endocrinology, Diabetes and Metabolism, Hematology and Rheumatology at Graduate School of Medicine, University of the Ryukyus.

References

[1] Shimoyama M, Members of the Lymphoma Study Group. Diagnostic criteria and classification of clinical subtypes of adult T-cell leukemia-lymphoma. Br J Hematol. 1991;79:428–437.

[2] Tsukasaki K, Utsunomiya A, Fukuda H, et al. VCAP-AMP-VECP compared with biweekly CHOP for adult T-cell leukemia-lymphoma; Japan clinical oncology group study JC09801. J Clin Oncol. 2007;25:5458–5464.

[3] Barrington SF, Mikhaeel NG, Kostakoglu L, et al. Role of imaging in the staging and response assessment of lymphoma: consensus of the International Conference on Malignant Lymphomas Imaging Working Group. J Clin Oncol. 2014;32:3048–3058.

[4] Cheson BD, Fisher RI, Barrington SF, et al. Recommendations for initial evaluation, staging, and response assessment of hodgkin and non-hodgkin lymphoma: the Lugano Classification. J Clin Oncol. 2014;32:3059–3067.

[5] Kikuchi M, Nakamoto Y, Shinohara S. Early evaluation of neo-adjuvant chemotherapy response using FDG-PET/CT predicts survival prognosis in patients with head and neck squamous cell carcinoma. Int J Clin Oncol. 2013;18:402–410.

[6] Schöder H, Noy A, Gönen M, et al. Intensity of 18fluoro-deoxyglucose uptake in positron emission tomography distinguishes between indolent and aggressive non-Hodgkin’s lymphoma. J Clin Oncol. 2005;23:4643–4651.

[7] Tateishi U, Tatsumi M, Terauchi T, et al. Prognostic significance of metabolic tumor burden by positron emission tomography/computed tomography in patients with relapsed/refractory diffuse large B-cell lymphoma. Cancer Sci. 2015;106:186–193.

[8] Kim TM, Paeng JC, Chun IK, et al. Total glycolysis in positron emission tomography is a better predictor of outcome than the International Prognostic Index for patients with diffuse large B cell lymphoma. Cancer. 2013;119:1195–1202.

[9] Song MK, Chung JS, Shin HJ, et al. Prognostic value of metabolic tumor volume on PET/CT in primary gastrointestinal diffuse large B cell lymphoma. Cancer Sci. 2012;103:477–482.

[10] Akamatsu G, Ikari Y, Nishida H, et al. Influence of statistical fluctuation on reproducibility and accuracy of SUVmax and SUVpeak: a Phantom Study. J Nucl Med Technol. 2015;43:222–226.

[11] Ceriani L, Martelli M, Zinzani PL, et al. Utility of baseline 18FDG-PET/CT functional parameters in defining prognosis of primary mediastinal (thymic) large B-cell lymphoma. Blood. 2015;126:950–956.

[12] Boellaard R, Delgado-Bolton R, Oyen WJG, et al. FDG PET/CT: EANM procedure guideline for tumour imaging: version 2.0. Eur J Nucl Med Mol Imaging. 2015;42:328–354.

[13] Kanda Y. Investigation of the freely available easy-to-use software ‘EZR’ for medical statistics. Bone Marrow Transplant. 2013;48:452–458.

[14] Kundel HL, Polansky M. Measurement of observer agreement. Radiology. 2003;228:303–308.

[15] Ohshima K, Kikuchi M, Masuda Y, et al. Human T-cell leukemia virus type I associated lymphadenitis. Cancer. 1992;69:239–248.

[16] Ohshima K. Pathological features of diseases associated with human T-cell leukemia virus type I. Cancer Sci. 2007;98:772–778.

[17] Ørbæk M, Graff J, Markova E, et al. 18F-FDG PET/CT Findings in acute Epstein-Barr virus infection mimicking malignant lymphoma. Diagnostics. 2016;6(2):18.

[18] Van Velden FHP, Cheesbunon P, Yaqud M, et al. Evaluation of a cumulative SUV-volume histogram method for parameterizing heterogeneous intratumoural FDG uptake in non-small cell lung cancer PET studies. Eur J Nucl Med Mol Imaging. 2011;38:1636–1647.

[19] Okada M, Sato N, Ishii K, et al. FDG PET/CT versus CT, MR imaging, and 67Ga scintigraphy in the post-therapy evaluation of malignant lymphoma. RadioGraphics. 2010;30:939–957.

[20] Otero HJ, Jagannathan JP, Prevedello LM, et al. CT and PET/CT findings of T-cell lymphoma. AJR. 2010;195:333–340.

[21] Freeney J, Horvitz S, Gönen M, et al. Characterization of T-cell lymphomas by FDG PET/CT. AJR. 2010;195:333–340.

[22] Casulo C, Schöder H, Freeney J, et al. 18F-fluorodeoxyglucose positron emission tomography in the staging and prognosis of T cell lymphoma. Leuk Lymphoma. 2013;54:2167–2167.

[23] Watanabe N, Murakami J, Kameda K, et al. F-18 FDG-PET/CT imaging in adult T-cell leukemia lymphoma. J Nucl Med. 2008;49:423–425.

[24] Kaida H, Kurata S, Hirose Y, et al. Hypermetabolic pulmonary and bone marrow lesions in a patient with chronic adult T-cell leukemia and description of this rare disease. J Nucl Med. 2014;17:145–147.

[25] Takahashi T, Ysukuda H, Itoh H, et al. Primary and isolated adult T-cell leukemia/lymphoma of the bone marrow. Intern Med. 2011;50:2393–2396.